OpenEvidence is booming despite questions about accuracy and ads. How should clinicians assess an advertising-supported AI tool before relying on it in their practice?

WHAT WAS ASKED

A clinician-facing question about OpenEvidence specifically: how should a practitioner evaluate an advertising-supported AI tool before trusting it in practice? The question names the tool, names the two concerns (accuracy, ads), and asks for an assessment method.

WHERE THE PANEL DISAGREED

Three positions warrant examination before the consensus is accepted.

The accuracy figures from the search-enabled response. One response cites a preprint reporting 41% accuracy on "Deep Consult" and 34% on "Quick Consult" for complex subspecialty cases. No other panel member surfaces this figure. It is unconfirmed and the preprint is not peer-reviewed, but the directional finding, that OpenEvidence performs substantially worse on complex cases than on exam-style questions, is consistent with what is known about retrieval-augmented LLMs generally. This is not a position that disagrees without grounds. It changes the practical framing: the relevant accuracy question is not average performance but performance at the tail, which is exactly where clinical stakes are highest.

The regulatory framing. Two responses invoke FDA clearance as a meaningful evaluative filter. One flags that most clinical AI search tools deliberately position themselves as "educational" or "reference" tools to avoid SaMD classification, which means FDA clearance will almost always be absent, making it a question that sounds rigorous but resolves trivially. This is a real tension the other responses did not handle cleanly. The FDA filter matters for tools making diagnostic or treatment decisions, but for a literature-retrieval and summarization tool like OpenEvidence, it is structurally inapplicable. The evaluation framework should not treat its absence as a red flag when regulatory design explains the absence.

The question of whether ad-support is structurally different from other conflicts of interest. No panel member argued this position, which means it is unrepresented in the synthesis. The strongest counter-argument to treating ad-support as a uniquely elevated risk is that traditional clinical reference tools, UpToDate, drug databases, journal supplements, also carry commercial relationships that can influence content, and clinicians use them without the same scrutiny. The honest critical position is that ad-support in AI is a new version of a familiar problem, not a categorically new problem. This matters for calibrating clinician response: total skepticism applied to AI but not to legacy tools is an inconsistency that will not hold under examination.

HOW STRONG THE AGREEMENT IS

The panel converged on five evaluative domains: accuracy verification, advertising transparency, data privacy, regulatory status, and maintaining clinician judgment as the final authority. That convergence is genuine on some points and fragile on others.

The convergence on accuracy verification is sound. It would be overturned if OpenEvidence or a comparable tool published prospective outcome data showing real-world clinical decisions made with the tool led to equivalent or better outcomes than decisions made without it. No such data exists. The consensus holds.

The convergence on advertising transparency as a necessary condition is partly circular. All four responses treat disclosed, firewall-separated advertising as the acceptable form. None examined whether a well-disclosed ad model still systematically biases retrieval in ways that are invisible to the user, for example, through training data selection, ranking weights, or framing of confidence language. The agreement on "disclosure as sufficient safeguard" was not examined; it was assumed. A rigorous counter-argument would note that disclosed bias is still bias, and that the audit mechanism required to verify independence is not currently available to individual clinicians. This weakens the advertising-transparency section from a verified finding to a reasonable heuristic.

The convergence on data privacy is standard and holds.

The convergence on "clinician judgment remains primary" is true but functionally incomplete as a safeguard. Over-reliance studies in cognitive psychology consistently show that when an AI output is presented with confident language and apparent citation support, clinicians anchor to it even when they intend not to. The consensus does not address this. It is the most credible argument that the standard "use as a second opinion" framing is insufficient, and it was not raised by any panel member.

WHAT THIS MEANS

The panel produced a competent checklist. It did not produce a decision framework. There is a difference.

A checklist tells a clinician what to look for. A decision framework tells a clinician what to conclude when they find it, or don't find it, and what to do next. The panel's convergence on "be rigorous, stay cautious" is correct but leaves the clinician at the same point they started: knowing they should evaluate carefully but not knowing where the threshold is.

Two findings from the panel, when combined, sharpen the answer. First, the accuracy problem is tail-weighted: OpenEvidence may perform well on common presentations and fail on the complex cases where a clinician most needs accurate synthesis. Second, the advertising-influence problem is not fully inspectable by the individual clinician, an audit of whether ads affect retrieval weighting requires access to the model internals that OpenEvidence does not make public. These two findings together mean the evaluation framework needs to be explicit about use restriction, not just use caution.

The pattern in the panel's reasoning is consistent across all four responses: each framed the problem as "how to evaluate and then decide whether to use the tool," when the more defensible frame for the current evidence state is "what uses are defensible now, and under what conditions might that change."

BOTTOM LINE

Clinicians should proceed on a use-restriction model, not an evaluation-then-trust model.

The distinction matters. Evaluation determines what you know about the tool. Use restriction determines what you do with that knowledge. Given that accuracy at the tail is the open question, that advertising-influence audits are not independently available, and that anchoring risk is real, the current defensible perimeter is narrow: literature retrieval, guideline identification, and background reading on familiar presentations. That perimeter should hold until two conditions are met, peer-reviewed prospective performance data on complex real-world cases, and an independently auditable advertising-firewall policy.

For each specific evaluation step, the sequence is:

Advertising transparency first. If sponsored content is not visibly and consistently distinguished from clinical synthesis, stop. The tool is not usable for clinical purposes regardless of its other properties.

Citation integrity second. Pull the primary source on every consequential claim before acting on it. Not occasionally. Every time. Citation presence does not establish citation accuracy. This is not a scalability objection to the tool, it is the professional standard that applies to any synthesized source.

Tail performance third. Test the tool on cases you already know are complex, multimorbid, or involve recent guideline changes. Average accuracy on common presentations is not the relevant metric. Performance on the cases where you most need help is.

Data governance fourth. Confirm that no identifiable patient information enters the query interface unless your institution has executed a compliant data processing agreement with the vendor.

Scope discipline ongoing. Build an explicit list of prohibited use cases, acute undifferentiated presentations, dosing calculations for high-risk medications, triage decisions, and treat that list as a standing institutional policy, not a personal preference.

The decisive factor is tail performance and unauditable commercial influence operating simultaneously. Either one alone is manageable. Together, they concentrate the risk precisely at the cases where the tool's confident, citation-rich output is most likely to be trusted and least likely to be correct.

This verdict changes if OpenEvidence or an independent group publishes prospective, specialty-validated, complex-case performance data alongside a third-party audit of advertising-content separation. Neither currently exists.

The actionable directive: implement a formal scope policy before deploying the tool in practice. A tool used without a scope policy is not being evaluated, it is being used.